Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background Blood pressure reduction achieved with beta-blockers and diuretics is the best recorded intervention to date for prevention of cardiovascular morbidity and death in patients with hypertension. Left ventricular hypertrophy (LVH) is a strong independent indicator of risk of cardiovascular morbidity and death. We aimed to establish whether selective blocking of angiotensin II improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death. Methods We did a double-masked, randomised, parallel-group trial in 9193 participants aged 55-80 years with essential hypertension (sitting blood pressure 160-200/95-115 mm Hg) and LVH ascertained by electrocardiography (ECG). We assigned participants once daily losartan-based or atenolol-based antihypertensive treatment for at least 4 years and until 1040 patients had a primary cardiovascular event (death, myocardial infarction, or stroke). We used Cox regression analysis to compare regimens. Findings Blood pressure fell by 30.2/16.6 (SD 18.5/10.1) and 29.1/16.8 mm Hg (19.2/10.1) in the losartan and atenolol groups, respectively. The primary composite endpoint occurred in 508 losartan (23.8 per 1000 patient-years) and 588 atenolol patients (27.9 per 1000 patient-years; relative risk 0.87, 95% CI 0.77-0.98, p=0.021). 204 losartan and 234 atenolol patients died from cardiovascular disease (0.89, 0.73-1.07, p=0.206); 232 and 309, respectively, had fatal or non-fatal stroke (0.75, 0.63-0.89, p=…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an 11% reduction in myocardial infarction (MI)”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“This study showed that each 10 mm Hg decrease in systolic BP (achieved with either an ACE inhibitor [captopril] or a beta blocker [atenolol]) was associated with a 15% reduction in DM-related mortality”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“and a 13% reduction in the microvascular complications of retinopathy or DKD.186”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Clinical trial data show that intensifying therapy with BP-lowering medications slows the progression of DKD and retinopathy, though vigilance in monitoring renal function during intensive BP therapy is recommended.185,186,201–203”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Optimization of glucose and BP are the proven strategies for primary prevention of diabetic retinopathy and for slowing the progression of preexisting nonproliferative retinopathy.78,185,186,193,522,523”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Hansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., Luomanmäki, K., Dahlöf, B., de Faire, U., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 2,014
Self-citationMorbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., Ekbom, T., & Wester, P.-O. (1991) · The Lancet · doi:10.1016/0140-6736(91)92589-t · Cited by 1,881
Self-citationAn updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
The Norwegian Multicenter Study Group (1981) · New England Journal of Medicine · doi:10.1056/nejm198104023041401 · Cited by 1,675
Hansson, L., Lindholm, L. H., Ekbom, T., Dahlöf, B., Lanke, J., Scherstén, B., Wester, P.-O., Hedner, T., & de Faire, U. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10327-1 · Cited by 1,447
Self-citationReversal of Left Ventricular Hypertrophy in Hypertensive Patients
Dahlöf, B., Pennert, K., & Hansson, L. (1992) · American Journal of Hypertension · doi:10.1093/ajh/5.2.95 · Cited by 925
Self-citationLemon, D. (1987) · The Journal of Emergency Medicine · doi:10.1016/0736-4679(87)90192-2 · Cited by 563
Casale, P. N., Devereux, R. B., Alonso, D. R., Campo, E., & Kligfield, P. (1987) · Circulation · doi:10.1161/01.cir.75.3.565 · Cited by 561
Self-citationMathew, J., Sleight, P., Lonn, E., Johnstone, D., Pogue, J., Yi, Q., Bosch, J., Sussex, B., Probstfield, J., & Yusuf, S. (2001) · Circulation · doi:10.1161/hc3901.096700 · Cited by 557
Brenner, B. M., Cooper, M. E., & de Zeeuw, D. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00549-9 · Cited by 508
Okin, P. M., Roman, M. J., Devereux, R. B., & Kligfield, P. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)00371-v · Cited by 395
Self-citationKjekshus, J. K. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90888-x · Cited by 357
(1997) · American Journal of Hypertension · doi:10.1016/s0895-7061(97)00054-x · Cited by 307
Characteristics of 9194 Patients With Left Ventricular Hypertrophy: The LIFE Study
Dahlöf, B., Devereux, R. B., Julius, S., Kjeldsen, S. E., Beevers, G., de Faire, U., Fyhrquist, F., Hedner, T., Ibsen, H., Kristianson, K., et al. (1998) · Hypertension · doi:10.1161/01.hyp.32.6.989 · Cited by 294
Self-citationVerdecchia, P., Porcellati, C., Reboldi, G., Gattobigio, R., Borgioni, C., Pearson, T. A., & Ambrosio, G. (2001) · Circulation · doi:10.1161/hc4201.097944 · Cited by 292
Improved electrocardiographic diagnosis of left ventricular hypertrophy
Schillaci, G., Verdecchia, P., Borgioni, C., Ciucci, A., Guerrieri, M., Zampi, I., Battistelli, M., Bartoccini, C., & Porcellati, C. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90316-6 · Cited by 248
Devereux, R. B., Agabiti-Rosei, E., Dahl??f, B., Gosse, P., Hahn, R. T., Okin, P. M., & Roman, M. J. (1996) · Journal of Hypertension · doi:10.1097/00004872-199609002-00018 · Cited by 176
Self-citationKjeldsen, S. E., Julius, S., Hedner, T., & Hansson, L. (2001) · Blood Pressure · doi:10.1080/08037050152669684 · Cited by 129
Self-citationDevereux, R. B., Bella, J., Boman, K., Gerdts, E., Nieminen, M. S., Rokkedal, J., Papademetriou, V., Wachtell, K., Wright, J., Paranicas, M., et al. (2001) · Blood Pressure · doi:10.1080/08037050152112050 · Cited by 125
Self-citationNorman, J. E., & Levy, D. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00269-5 · Cited by 112
Okin, P. M., Roman, M. J., Devereux, R. B., & Kligfield, P. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00421-1 · Cited by 109
Self-citationAngiotensin II Receptor Antagonists: An Emerging New Class of Cardiovascular Therapeutics.
Timmermans, P. B. M. W. M. (1999) · Hypertension Research · doi:10.1291/hypres.22.147 · Cited by 106
Dahlöf, B., Keller, S. E., Makris, L., Goldberg, A. I., Sweet, C. S., & Lim, N. Y. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)00081-y · Cited by 103
Self-citationLeft ventricular hypertrophy and angiotensin II antagonists
Dahlöf, B. (2001) · American Journal of Hypertension · doi:10.1016/s0895-7061(00)01257-7 · Cited by 79
Self-citationBrunner, H. R. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01538-7 · Cited by 74
Kjeldsen, S. E., Dahlof, B., Devereux, R. B., Julius, S., de Faire, U., Fyhrquist, F., Ibsen, H., Kristianson, K., Lederballe-Pedersen, O., Lindholm, L. H., et al. (2000) · American Journal of Hypertension · doi:10.1016/s0895-7061(00)00280-6 · Cited by 60
Self-citation
Research works printed but not linked: 2
- Dhlöf, 1997, The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods, Am J Hypertens, 10, 705
- Mulrow, 2001, Pharmacotherapy for hypertension in the elderly (Cochrane review)
Cited by
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Self-citation(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Self-citationChobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Self-citation2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Self-citationInflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Metadata
- Authors
- Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., Lindholm, L. H., Nieminen, M. S., Omvik, P., Oparil, S., & Wedel, H.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Oslo University Hospital (NO)
- University of Michigan (US)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- Glostrup Hospital (DK)
- Umeå University (SE)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Corresponding author
- Dahlöf, Björn
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 995-1003
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2133217116
- Cited by
- 5,407
- References
- 29
- Citations by year
- 2026: 37 · 2025: 51 · 2024: 51 · 2023: 69 · 2022: 63 · 2021: 75 · 2020: 74 · 2019: 82 · 2018: 106 · 2017: 144 · 2016: 131 · 2015: 152 · 2014: 208 · 2013: 200 · 2012: 265
- FWCI
- 333.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Keywords
- atenolol, essential hypertension, left ventricular hypertrophy, angiotensin receptor blockers, beta-blockers, cardiovascular morbidity, cardiovascular mortality, stroke, myocardial infarction, blood pressure reduction, new-onset diabetes, antihypertensive therapy, elderly patients, secondary prevention of cardiovascular disease, renin-angiotensin system blockade
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.